Stano-Med, Stanozolol Injection USP, 100 mg/ml, 10 ml

Stanozolol 100 mg/ml by Bioniche Pharma is a high-potency parenteral anabolic agent formulated as a micro-crystalline aqueous suspension of a $17\alpha$-alkylated dihydrotestosterone (DHT) derivative. Engineered by Bioniche Pharma for swift systemic absorption without ester modification, Bioniche Pharma Stanozolol delivers strong non-estrogenic anabolic action, improves cellular nitrogen conservation, and encourages structural protein synthesis.

CLINICAL PHARMACOLOGY & MECHANISM OF ACTION

Stanozolol by Bioniche Pharma operates via direct interaction with nuclear androgen receptors, accelerating skeletal muscle tissue repair and suppressing catabolic degradation. Being non-aromatizable, Bioniche Pharma Stanozolol presents no intrinsic risk of converting to estrogen, preventing estrogenic fluid accumulation and gynecomastia while raising serum C1 esterase inhibitor levels in therapeutic applications.

INDICATIONS & CLINICAL USE

• Prophylactic management and reduction of acute attacks in hereditary or acquired angioedema using Bioniche Pharma Stanozolol.
• Palliative therapeutic support for postmenopausal women with advanced, hormone-sensitive breast carcinoma.
• Adjunctive treatment to enhance bone mineral density and matrix formation in severe osteoporosis under clinical direction.

CONTRAINDICATIONS

• Male individuals with diagnosed or suspected prostate carcinoma or breast cancer.
• Female breast carcinoma accompanied by severe hypercalcemia (elevated serum calcium levels).
• Severe renal failure, nephrotic syndrome, or advanced primary hepatic disease.
• Pregnancy and lactation due to high risks of female fetal masculinization and systemic endocrine toxicity.
• Documented allergy or hypersensitivity to Stanozolol or formulation excipients in Bioniche Pharma injectables.

PRECAUTIONS & CLINICAL MONITORS

• Glycemic Control: Because anabolic agents can modify peripheral insulin sensitivity and glucose uptake, diabetic patients receiving Bioniche Pharma Stanozolol should test blood glucose levels regularly, as anti-diabetic medication adjustments may be required.
• Pediatric Caution: Extreme vigilance is required in young patients due to heightened sensitivity to androgenic effects, potential precocious puberty, and premature epiphyseal plate fusion.
• Lipid Profile & Hepatic Surveillance: As a $17\alpha$-alkylated aqueous formulation, routine monitoring of liver transaminases (AST/ALT), serum bilirubin, and lipid panel parameters (elevation of LDL, reduction of HDL) is strongly advised during Bioniche Pharma Stanozolol therapy.

ADVERSE REACTIONS

• Dermatological & Androgenic: Seborrhea, severe acne vulgaris, facial or body hirsutism, and accelerated male pattern baldness (androgenetic alopecia) in predisposed individuals.
• Endocrine & Hepatic: Dose-dependent suppression of the endogenous hypothalamic-pituitary-gonadal (HPG) axis, hepatic transaminase elevations, and potential cholestatic jaundice with prolonged use of Bioniche Pharma Stanozolol.

DOSAGE & ADMINISTRATION

Stanozolol by Bioniche Pharma is supplied as an aqueous micro-crystalline suspension requiring thorough shaking of the vial prior to aspiration. Administer strictly via deep intramuscular injection:

• Dosage Schedule: Standard clinical protocols typically call for injections 2 to 3 times weekly, with cumulative weekly dosages ranging between 200 mg and 300 mg of Bioniche Pharma Stanozolol under qualified healthcare supervision.

STORAGE & HANDLING

Store Bioniche Pharma Stanozolol in a dry, cool location protected from direct light exposure, extreme heat, and freezing temperatures. Store safely out of the reach and sight of children.